Toxoplasmosis in AIDS: Keeping the Lid On
Authors: Joseph A. Kovacs
Journal: Annals of Internal Medicine (1995)

Editorials1 August 1995Toxoplasmosis in AIDS: Keeping the Lid OnJoseph A. Kovacs, MDJoseph A. Kovacs, MDNational Institutes of Health, Bethesda, MD 20892-1662Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-3-199508010-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The management of toxoplasmic encephalitis in patients with human immunodeficiency virus (HIV) infection has been a continuously evolving process. Changes in management strategies have been made largely on the basis of clinical experiences, retrospective studies, and small, uncontrolled trials [1]. Currently, HIV-infected patients with neurologic symptoms, low CD4 counts (<100 cells/mm3), and compatible radiographic scans are usually treated empirically for Toxoplasma gondii encephalitis. Acute empiric therapy is usually initiated with either pyrimethamine-sulfadiazine or pyrimethamine-clindamycin [2, 3]; evidence of clinical improvement is seen within 1 to 2 weeks in most responding patients receiving these therapies [4, 5]. Acute therapy is continued ...References1. Wong SY, Israelski DM, Remington JS. AIDS-associated toxoplasmosis. In: Sande MA, Volberding PA, eds. The Medical Management of AIDS. Philadelphia: WB Saunders; 1995:460-93. Google Scholar2. Katlama C, De Wit S, Guichard A, van Pottelsberhe C, Van Glabeke M, Clumeck N, et al. A randomized European trial comparing pyrimethamine-clindamycin to pyrimethamine-sulfadiazine in AIDS toxoplasmic encephalitis. Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1992:313 (Abstract 1215). Google Scholar3. Dannemann BR, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med. 1992; 116:33-43. Google Scholar4. Luft BJ, Hafner R, Korzun AH, Leport C, Antoniskis D, Bosler EM, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med. 1993; 329:995-1000. Google Scholar5. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in he acquired immunodeficiency syndrome. N Engl J Med. 1992; 327:1643-8. Google Scholar6. Kovacs JA. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet. 1992; 340:637-8. Google Scholar7. Canessa A, Del Bono V, De Leo P, Piersantelli N, Terragna A. Cotri-moxazole therapy of Toxoplasma gondii encephalitis in AIDS patients. Eur J Clin Microbiol Infect Dis. 1992; 11:125-30. Google Scholar8. Ward D. Dapsone/pyrimethamine for the treatment of toxoplasmic encephalitis (Abstract). Abstracts of the VIII International Conference on AIDS. 1992; 8:B133-PoB 3277. Google Scholar9. Saba J, Morlat P, Raffi F, Hazebroucq V, Joly V, Leport C. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis. 1993; 12:853-6. Google Scholar10. Fernandez-Martin J, Leport C, Morlat P, Meyohas MC, Chauvin JP, Vilde JL. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother. 1991; 35:2049-52. Google Scholar11. Pedrol E, Gonzalez-Clemente JM, Gatell JM, Mallolas J, Miro JM, Graus F, et al. Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy. AIDS. 1990; 4:511-7. Google Scholar12. Leport C, Tournerie C, Raguin G, Fernandez-Martin J, Niyongabo T, Vilde JL. Long-term follow-up of patients with AIDS on maintenance therapy for toxoplasmosis. Eur J Clin Microbiol Infect Dis. 1991; 10:191-3. Google Scholar13. Podzamczer D, Miro JM, Bolao F, Gatell JM, Cosin J, Sirera G, et al. Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1995; 123:175-80. Google Scholar14. Heald A, Flepp M, Chave JP, Malinverni R, Ruttimann S, Gabriel V, et al. Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. The Swiss HIV Cohort Study. Ann Intern Med. 1991; 115:760-3. Google Scholar15. Weiss LM, Harris C, Berger M, Tanowitz HB, Wittner M. Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis. 1988; 157:580-3. Google Scholar16. Carr A, Tindall B, Brew BJ, Marriott DJ, Harkness JL, Penny R, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1992; 117:106-11. Google Scholar17. Ruf B, Schurmann D, Bergmann F, Schuler-Maue W, Grunewald T, Gottschalk HJ, et al. Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1993; 12:325-9. Google Scholar18. de Gans J, Portegies P, Reiss P, Troost D, van Gool T, Lange JM. Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS. J Acquir Immune Defic Syndr. 1992; 5:137-42. Google Scholar19. Moreno JN, Poblete RB, Maggio C, Gagnon S, Fischl MA. Rapid oral desensitization for sulfonamides in patients with the acquired immunodeficiency syndrome. Ann Allergy Asthma Immunol. 1995; 74:140-6. Google Scholar20. Schneider MM, Nielsen TL, Nelsing S, Hoepelman AI, Schattenkerk JK, Van Der Graaf Y. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. J Infect Dis. 1995; 171:1632-6. Google Scholar Author, Article, and Disclosure InformationAffiliations: National Institutes of Health, Bethesda, MD 20892-1662Corresponding Author: Joseph A. Kovacs, MD, Building 10, Room 7D43, 10 Center Drive, MSC 1662, Bethesda, MD 20892-1662. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTwice-Weekly Maintenance Therapy with Sulfadiazine-Pyrimethamine To Prevent Recurrent Toxoplasmic Encephalitis in Patients with AIDS Daniel Podzamczer , Jose M. Miro , Ferran Bolao , Jose M. Gatell , Jaime Cosin , Gillem Sirera , Pere Domingo , Fernando Laguna , Juan Santamaria , Jose Verdejo , and Metrics Cited ByHuman Toxoplasma infectionHuman Toxoplasma InfectionToxoplasmosisComparison of High and Low Doses of Trimethoprim-Sulfamethoxazole for Primary Prevention of Toxoplasmic Encephalitis in Human Immunodeficiency Virus-Infected PatientsToxoplasma encephalitis in a HIV patient: unusual involvement of the corpus callosumTreatment regimens for patients with toxoplasmic encephalitis 1 August 1995Volume 123, Issue 3Page: 230-231KeywordsAdverse reactionsDrug therapyDrugsEncephalitisPneumoniaProphylaxisPyrimethamineRetrospective studiesToxicityToxoplasmosis Issue Published: 1 August 1995 CopyrightCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...